Nestle has refused to comment on a report in the US claiming the world’s largest food maker is considering a takeover offer for infant formula producer Mead Johnson.

Financial news portal Street Insider said yesterday (18 January) Credit Suisse was advising Nestle on a possible move for the Enfamil maker.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

“As a matter of principle we do not comment on market rumour,” a Nestle spokesperson told just-food.

A spokesperson for Mead Johnson said: “As a matter of policy, we do not comment on marketplace speculation or rumours.”

Takeover talk often centres on the future ownership of the US-based business, created when it was spun off from US pharma giant Bristol-Myers Squibb in 2010.

Last March, the Betaville blog claimed Mead Johnson had made contact with advisers at investment bank Lazard after Nestle and Danone had lodged interest in the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

There was a flurry of speculation linking Danone to Mead Johnson in the autumn of 2014. At the time, analyst reaction to the prospect of the French giant buying Mead Johnson was mixed. Some industry watchers questioned whether the Aptamil maker could afford Mead Johnson without a rights issue and suggested the group should instead invest in smaller transactions, which it subsequently did.